LONDON - Amarin Corporation plc announced in a Thursday press release that the United States Patent and Trademark Office (USPTO) has granted approval for its patent application covering the use of its proprietary ultra-pure ethyl-EPA compound (Miraxion) in Huntington’s disease, the patent, number 7,119,118, will run to 2021.
The CEO Rick Stewart stated, "We believe this patent substantially enhances Miraxion’s already significant commercial potential. Amarin has additional patents granted for Miraxion in other central nervous system disorders, such as depression, and has many patents pending for a range of indications. We are committed to further strengthening our existing intellectual property portfolio to protect the future market for Miraxion."
Amarin is a neuroscience company focused on the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.
